{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:15:14Z","timestamp":1781846114240,"version":"3.54.5"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia Open"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety of brivaracetam (BRV) as an add\u2010on therapy in patients with focal onset seizures who did not achieve seizure freedom with antiseizure medication (ASM) monotherapy in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, observational, multicenter study conducted across 17 neurology centers in Spain. We evaluated adult patients with focal onset epilepsy who had inadequate seizure control after at least 3 months of ASM monotherapy and were treated with dual therapy, combining BRV with their previous ASM, with the intention of maintaining this treatment for at least 6 months. Data were collected from medical records on seizure frequency, ASM doses, and adverse events (AEs), taking into account the end of this 6\u2010month period of dual therapy. The primary efficacy outcomes were the proportion of patients achieving \u226550% reduction in seizure frequency and those achieving seizure freedom. Safety outcomes included the incidence of treatment\u2010related AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 195 patients (mean age: 43.2\u2009years; 52.3% male; mean disease duration: 11.5\u2009years) were included in the study. The main location of epilepsy was identified (53.8%) as the frontal lobe (27.7%). The mean number of seizures during the last 3 months of ASM monotherapy was 12.1 (SD 39.5), which decreased to 6.4 (SD 21.2) after 6 months of BRV add\u2010on therapy. A \u2265\u200950% reduction in seizure frequency was achieved by 90.8% of patients, while 49.7% reached seizure freedom. The most common AEs were related to the central nervous system, reported by 22.1% of patients, with a treatment discontinuation rate due to AEs of 12.8%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>BRV as an add\u2010on therapy is effective in reducing seizure frequency and is well\u2010tolerated in patients with focal onset seizures. This study supports the use of BRV as an add\u2010on option in patients who do not achieve adequate seizure control with ASM monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain Language Summary<\/jats:title>\n                    <jats:p>This study evaluated how effective and safe brivaracetam (BRV) is when added to another medication for patients with focal onset seizures. The results showed that adding BRV helped many patients reduce the number of seizures, and some patients stopped having seizures completely. Side effects were generally mild.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/epi4.70073","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T14:45:21Z","timestamp":1756565121000},"page":"1334-1344","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and safety of early add\u2010on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice:\n                    <scp>BRIV<\/scp>\n                    \u2010add study"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-2707","authenticated-orcid":false,"given":"Pedro J.","family":"Serrano\u2010Castro","sequence":"first","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA\u2010Plataforma Bionand)  M\u00e1laga Spain"},{"name":"M\u00e1laga Regional University Hospital  M\u00e1laga Spain"},{"name":"Departamento de Medicina y Dermatolog\u00eda Universidad de M\u00e1laga  M\u00e1laga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-2824","authenticated-orcid":false,"given":"Fernando","family":"Caballero\u2010Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universidad Francisco de Vitoria  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-3384","authenticated-orcid":false,"given":"Francisco J.","family":"Campos\u2010Lucas","sequence":"additional","affiliation":[{"name":"Health Research Universidad Francisco de Vitoria  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Campos\u2010Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"de Aguilar\u2010Amat","sequence":"additional","affiliation":[{"name":"La Paz University Hospital  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Central University Hospital of Asturias  Oviedo Asturias Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Gifreu","sequence":"additional","affiliation":[{"name":"Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Santamar\u00eda\u2010Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Universidad Francisco de Vitoria  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8610-1467","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Poza","sequence":"additional","affiliation":[{"name":"Donostia University Hospital  San Sebasti\u00e1n Guip\u00fazcoa Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Toledo\u2010Argany","sequence":"additional","affiliation":[{"name":"Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Grupo de Investigadores Colaboradores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Organizaci\u00f3n Mundial de la Salud.Epilepsia. Datos y cifras.https:\/\/www.who.int\/es\/news\u2010room\/fact\u2010sheets\/detail\/epilepsy"},{"key":"e_1_2_12_3_1","unstructured":"Sociedad Espa\u00f1ola de Neurolog\u00eda (SEN).Manual de Pr\u00e1ctica Cl\u00ednica en Epilepsia. Recomendaciones diagn\u00f3stico\u2010terap\u00e9uticas de la SEN 2019. Actualizado en junio de 2023.http:\/\/guiaepilepsia.sen.es\/pdf\/GuiaEpilepsia.pdf"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/602710"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102513"},{"key":"e_1_2_12_6_1","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta\u2010analysis of individual participant data","volume":"4","author":"Nevitt SJ","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011501.pub2"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02876-z"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.73413"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12433"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12432"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13212"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12391"},{"key":"e_1_2_12_14_1","unstructured":"European Medicines Agency.Briviact: EPAR \u2013 Product Information [Internet].https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/briviact\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_12_15_1","unstructured":"U.S. Food and Drug Administration.BRIVIACT (brivaracetam) prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/205836s014 205837s011 205838s011lbl.pdf"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00402-3"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00697-4"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109922"},{"key":"e_1_2_12_19_1","unstructured":"EMA. Brivaracetam.Summary of product characteritics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/briviact\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ec7f7f"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03598.x"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13059"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108985"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107746"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00717-x"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01033-4"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106694"},{"issue":"5","key":"e_1_2_12_28_1","article-title":"Brivaracetam to treat partial onset seizures in adults","volume":"10","author":"Latimer D","year":"2022","journal-title":"Health Psychol Res"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.12.024"}],"container-title":["Epilepsia Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi4.70073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T10:32:07Z","timestamp":1764671527000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epi4.70073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/epi4.70073"],"URL":"https:\/\/doi.org\/10.1002\/epi4.70073","archive":["Portico"],"relation":{},"ISSN":["2470-9239","2470-9239"],"issn-type":[{"value":"2470-9239","type":"print"},{"value":"2470-9239","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"2025-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}